Skip to main
DBD
DBD logo

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc. has demonstrated robust growth in its Retail segment, with revenues reaching $255 million, reflecting an 8.1% increase quarter-over-quarter and a 7.8% rise year-over-year, alongside expanding gross margins. The company is poised to deliver sustainable free cash flow (FCF), projected to nearly double to an estimated $205 million in 2025, following positive FCF generation for four consecutive quarters. Furthermore, anticipated gross margin expansion and strong year-over-year EPS growth for 2026 underscore the positive financial trajectory and potential for profitability enhancement, particularly as management focuses on these metrics in upcoming earnings discussions.

Bears say

Diebold Nixdorf Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from technological missteps, a lack of innovation, and difficulties in protecting intellectual property, all of which threaten revenues and profitability. The company's Banking segment has also witnessed a decline in gross margins, which fell to 26.8%, indicating increased pricing pressure from competition and decreased demand for its products. Furthermore, management's expectation of reducing operational expenses by $50 million annually may not fully mitigate the adverse impacts of potential tariffs, supply chain disruptions, and fluctuating currency exchange rates, thereby raising concerns about the company’s overall financial stability and liquidity.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.